Trung Huynh

Chris confirmed both doses met primary and co-primary endpoints but deferred the full TRANQUILLO 1 data set to a later conference.

Bourla confirmed active discussions at highest government levels but declined specifics citing active negotiations; Denton added underlying business strength allows absorption of range of scenarios.

Management expects 65+ and at-risk populations indication, no major payer coverage changes, strong distribution capabilities; have not seen dramatic changes in intent to vaccinate.

Denton clarified $1.2B mostly 2026-2027 delivery, R&D $500M savings largely in 2025 to be reinvested in R&D.

Baum confirmed $10-15B BD budget intact; noted sellers adjusting to lower valuations in areas with increasing therapeutic density from Chinese innovation; Bourla quoted 'never let a good crisis go to waste.'

Malik declined to speculate on specific ACIP timing, redirecting to previously described growth catalysts.

Boshoff outlined event-driven readout timeline by year-end, 28,000 U.S. patients tripling addressable population, and two studies for cisplatin-eligible and cisplatin-ineligible.

Rob framed the pilot as bringing transparency and accountability to curb 340B abuse but declined to size any gross-to-net benefit yet.

Roopal said the CRL was on CMC, not safety or efficacy; resubmission comes at year-end with a 6-month review pointing to a U.S. decision around the middle of next year.

Scott Reents noted ~10-point differential between IQVIA data and actual volume due to induction disconnect. H1 price favorability driven by gating items and lighter-than-expected Part D redesign impact; expects neutral full-year Skyrizi pricing with negative price in H2.

Scott Reents attributed 72% operational growth mostly to demand in the 60s with modest benefit from lack of Q4 retail inventory destocking. China tariff impact absorbed in aesthetics guidance.

Scott Reents confirmed minimal stocking impact and no gross-to-net dynamics for Skyrizi and Rinvoq. Carrie Strom noted Japan as a growth market and international aesthetics share increasing.

Tied the program pause to a reagent change now corrected, said the company is working with regulators to restart, and called the sepsis death the program's only grade 5 event.

Adam declined to share specific rates but noted Q1 included a Q4 true-up. GTN will increase for full year due to 100% Medicaid/Medicare access.

Samit noted placebo-controlled design with NPI hallucinations/delusions as primary endpoint. No approved drugs sets low bar. Prior xanomeline data supportive.

Search underway but no rush. Former CCO (now COO) still involved. Launch preparation began two years ago, providing continuity. TPIP database cleaning is for registrational quality, not issues.

CFO described multiple financing options including equity, royalty deals, R&D funding, and debt. Line of sight to becoming self-sustaining but not yet funded through profitability.

Dan indexed ATTAIN expectations to SURMOUNT-5 semaglutide monotherapy result of ~13.7% weight loss. Noted GI events and discontinuations occurred early during dose escalation, not late.

Dan cautioned against using OA trial as comp: shorter duration (68 vs 80+ weeks), different demographics, and known efficacy diminution in OA populations. Expects better results in broader obesity.

Rob confirmed the bill would delay KEYTRUDA IRA implementation to 2029 but stressed it doesn't change Merck's focus on growing post-LOE.

Caroline said tariff exposure is immaterial; did not directly address the transfer pricing IP question on KEYTRUDA.